Total Voting Rights

RNS Number : 0653I
Oxford Biomedica PLC
28 June 2013

For Immediate Release

28 June 2013



Oxford BioMedica plc ("the Company")


Total Voting Rights Update


In accordance with the FCA's Disclosure and Transparency Rules, Oxford BioMedica plc (LSE:OXB) confirms that the Company's issued share capital consists of 1,416,149,005 ordinary shares of 1p each, all with voting rights.  No shares are held in treasury.


This figure may be used by shareholders as the denominator for the calculation by which they will determine whether they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure and Transparency Rules.




For further information, please contact:


Oxford BioMedica plc:

Lara Mott, Head of Corporate Communications


Tel: +44 (0)1865 783 000


Nomura Code Securities

Juliet Thompson/Jonathan Senior/Christopher Golden



Tel: +44 (0)20 7776 1200

Media Enquiries:

Mary-Jane Elliott/Sarah Macleod/Claire Dickinson M:Communications

Tel: +44 (0)20 7920 2360



Notes to editors


1. Oxford BioMedica®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at and


This information is provided by RNS
The company news service from the London Stock Exchange